← FDA DRUG APPROVALS

FDA ANDA · ANDA214856

ENOXAPARIN SODIUM

Sponsor: EMERGE BIOSCIENCE

APPLICATION
ANDA214856
TYPE
ANDA
ORIGINAL APPROVAL
2022-06-14
LATEST ACTION
2022-06-14
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ENOXAPARIN SODIUMPrescription
ENOXAPARIN SODIUM 300MG/3ML (100MG/ML) · INJECTABLE · INTRAVENOUS, SUBCUTANEOUS

Approval history

2022-06-14UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →